<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Investigational evidence seems to support the role of antiviral activity of chloroquine toward the SARS and avian influenza viruses in 
 <italic>inÂ vitro</italic> and animal models.
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> Clinical evidence to support their use remains limited at this time.
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> Because of similar molecular structure, a well-known immunomodulating effect,
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> and better safety profile, hydroxychloroquine may be considered as an option in this context,
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> and of interest its use has been found to be associated with a higher proportion of patients showing a negative reverse transcriptase-polymerase chain reaction from day 3 after its introduction compared with untreated controls in small series.
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref>
</p>
